Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Common and rare variant contributions to discontinuation of stimulant treatment in ADHD.

Translational psychiatry - 28 Feb 2026

Thirstrup Janne Pia, Duan Jinjie, Ribases Haro Marta, Soler Artigas Maria, Albiñana Clara, Dalsgaard Søren, Faraone Stephen V, Werge Thomas, Bybjerg-Grauholm Jonas, Børglum Anders D, Agerbo Esben, Yao Honghui, Chang Zheng, Brikell Isabell, Demontis Ditte

Abstract excerpt

Stimulants are the first-line pharmacological treatment for ADHD and generally effective, yet 35-61% of individuals discontinue treatment within a year. We investigated the contribution of common and rare genetic variants to early stimulant discontinuation using data from 18,362 individuals with ADHD (31% female) initiating stimulants in iPSYCH, a Danish population-based case-cohort linked to national registers....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Attention Deficit Disorder with Hyperactivity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Central Nervous System Stimulants

Share to Denmark

Share to Genetic Risk Score

Share to Genome-Wide Association Study

Share to Registries

Source

Open in PubMed Open full text

Identifiers

PMID: 41764167
DOI: 10.1038/s41398-026-03925-7
PMCID: PMC12987951

Genes

SLC5A12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Common and rare variant contributions to discontinuation of stimulant treatment in ADHD.PMID 41764167Read ↗

Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD.Semantic proximity Read ↗

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocolSemantic proximity Read ↗

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocolSemantic proximity Read ↗

Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder.Semantic proximity Read ↗

Demographic and Genetic Predictors of ADHD Diagnoses and Medications in Electronic Health RecordsSemantic proximity Read ↗

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.Semantic proximity Read ↗

Starting, stopping and restarting. Patterns of Methylphenidate Use over 14 years in a large public health systemSemantic proximity Read ↗

Evaluation of common variants in 16 genes involved in the regulation of neurotransmitter release in ADHD.Semantic proximity Read ↗

Replicated association of Synaptotagmin (SYT1) with ADHD and its broader influence in externalizing behaviors.Semantic proximity Read ↗

Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.Semantic proximity Read ↗

censusADHD Study: An Australian-wide medication-based recruitment study for Attention-Deficit/Hyperactivity DisorderSemantic proximity Read ↗

Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.